Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Losartan combined with bevacizumab plus chemotherapy in metastatic colorectal cancer
ChiCTR2400082666Phase 2Recruiting
- Sponsor
- Jiangjin Central Hospital
- Start
- Apr 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of losartan and bevacizumab in colorectal cancer (CRC) and metastatic colorectal adenocarcinoma (mCRC), sponsored by Jiangjin Central Hospital. Primary endpoint: Objective response rate. Started Apr 2024; status: recruiting.
02
Drugs
losartanbevacizumab
03
Conditions
colorectal cancer (CRC)metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on ChiCTR2400082666.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400082666.